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of commercially insured patients aged < 65 years and one of Medicare enrollees—
we identified all adult patients (≥ 18 years) with schizophrenia (ICD-9-CM 295.
XX) initiating treatment with asenapine versus OBAP between 2009 and 2012. All 
patients were required to be continuously enrolled for the 6-month periods before 
and after the date of the first prescription claim for asenapine or OBAP (this was 
deemed the “index date”). We used propensity-score matching to control for dif-
ferences between the groups. Changes in HRU and costs (2012 dollars) between the 
6 month pre- and post-index periods were calculated within each group and then 
compared across groups. RESULTS: A total of 259 asenapine patients were propen-
sity matched to an equal number of OBAP patients; matched groups were similar 
in terms of age (mean: 39.9 years for asenapine patients vs. 41.8 years for OBAP 
patients, p= 0.19), gender (58.7% vs. 56.8% female; p= 0.66); and Charlson comor-
bidity index (mean: 0.47 vs. 0.52, p= 0.65). Differences in HRU between the pre- 
and post-index periods nominally favored asenapine patients, including greater 
reductions in admissions (mean: -0.49 for asenapine patients vs. -0.40 for OBAP 
patients, p= 0.38) and emergency room visits (-0.19 vs. -0.08, p= 0.26); decreases 
in total healthcare costs also favored asenapine patients ($-7,609 vs. $-5,585, 
p= 0.45). While pharmacy costs increased in both groups, the increase was signifi-
cantly lower among asenapine patients ($922 vs. $1,707, p< 0.05). CONCLUSIONS: 
Initiation of asenapine for schizophrenia is associated with significantly lower 
pharmacy costs than OBAP, and nominally greater decreases in levels of HRU and 
total healthcare costs.
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OBJECTIVES: Abuse of prescription opioid medications through tampering, such 
as the chewing or crushing of pills, is associated with greater healthcare use. 
This study was conducted to assess the economic cost of such tampering in the 
United States. METHODS: Participants from the US National Health and Wellness 
Survey were recontacted for an online survey assessing use, misuse, and abuse 
of prescription opioid medications. All measures were self-reported. Abuse was 
defined as taking prescription opioid medication for the purpose of getting high 
in the prior 3 months, and use of the medication in any form other than the 
original was considered tampering. Direct medical costs were estimated by apply-
ing unit costs to self-reported healthcare visits. Unit costs were sourced from 
the Truven Market Scan (TMS) database, and the analysis was repeated using 
unit costs from the Medical Expenditure Panel Survey (MEPS). Respondents who 
reported abuse of prescription opioids through tampering were compared to those 
who reported abuse without tampering. Costs were compared using bivariate 
statistics as well as generalized linear models (GLMs) to adjust for confound-
ers. RESULTS: Those who abused through tampering had significantly higher 
estimated healthcare costs during the 3-month recall period, with mean (unad-
justed) incremental cost of $18,814 using TMS unit costs (p< 0.001). This included 
higher mean costs for non-opioid-related medical visits ($11,944, p< 0.001), opi-
oid-related medical visits ($6,567, p< 0.001), and drug rehabilitation costs ($303, 
p< 0.001). Median total incremental costs were also higher by $3,803. GLMs indi-
cated increased total direct costs with tampering after adjusting for confound-
ers (p< 0.001). Conclusions were similar using MEPS unit costs. CONCLUSIONS: 
Tampering with prescription opioid medications in order to get high is associated 
with significantly increased medical costs compared to those who abuse with-
out tampering. Efforts to reduce tampering, such as the use of abuse-deterrent 
formulations of prescription opioid medications, may provide net healthcare 
savings.
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OBJECTIVES: To assess differences in healthcare costs associated with ini-
tiation of asenapine versus aripiprazole among patients with bipolar disorder 
(BD). METHODS: We used two large US healthcare claims databases that collec-
tively included commercially insured patients aged < 65 years and Medicare enroll-
ees to identify all adults (≥ 18 years) with BD (ICD-9-CM diagnosis codes 296.0X, 
296.1X, 296.4X, 296.6X, 296.7X, 296.80, 296.81, 296.89) who began therapy with 
asenapine or aripiprazole between 2009 and 2012. Patients without continuous 
enrollment for the 6-month periods before and after the date of the first prescrip-
tion claim for asenapine or aripiprazole (“index date”) were excluded. Asenapine 
patients were then matched to aripiprazole patients using propensity scoring to 
control for differences between the groups. HRU and associated costs (2012 dol-
lars) were deemed BD-related based on the presence of a BD diagnosis code on the 
relevant claim. Within each group, differences in BD-related HRU and costs were 
estimated between the pre- and post- index periods, and then compared across 
groups. RESULTS: A total of 2680 patients were included in the analyses (n= 1,340 
for each group); the groups were comparable with respect to age (mean age: 42.8 
years for asenapine patients vs. 42.2 years for aripiprazole patients, p= 0.27), per-
cent female (70.3% vs. 70.1%, p= 0.90), and Charlson comorbidity index (mean: 
0.45 vs. 0.42, p= 0.55). Asenapine patients had nearly a twofold greater decrease 
in total BD-related healthcare costs than aripiprazole patients (mean: -$863 for 
asenapine vs. -$490 for aripiprazole, p< 0.05); BD-related outpatient costs also 
exhibited a significant decrease ($-2 vs. a $10 increase for aripiprazole patients, 
p< 0.05). While pharmacy costs increased in both groups, the increase was signifi-
cantly lower among asenapine patients ($886 vs. $1,518, p< 0.05). CONCLUSIONS: 
As compared with aripiprazole, asenapine was associated with a reduction in 
total healthcare costs related to BD during the 6-month period following therapy 
initiation.
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OBJECTIVES: To estimate the national costs of prescription medications for child-
hood attention deficit hyperactivity disorder (ADHD) in the United States (U.S.) in 
2010 and to identify differences in diagnosis and costs by gender and racial/ethnic 
background. METHODS: To determine childhood ADHD diagnosis and prescription 
medication use, we used ICD-9 and drug ID codes recorded from pediatric visits in 
the 2010 National Ambulatory Medical Care Survey (NAMCS). Our analysis included 
all formulations of the following medications: amphetamine salts, atomoxetine, 
dextroamphetamine, dexmethylphenidate, and methylphenidate. To calculate the 
costs of medication use, we multiplied the 2010 average wholesale price (AWP) by a 
presumed usual number of yearly doses and weighed these costs to reflect national 
estimates. We compared differences in overall medication cost by gender and race 
using the student’s t test and evaluated differences in the proportion of patients 
diagnosed with ADHD using the chi-square test. RESULTS: Among pediatric visits in 
2010, we found that 5.70% (n= 7,201,548) were associated with a diagnosis of ADHD 
and, of those diagnosed, 67.29% (n= 4,846,163) had a mention of a prescribed ADHD 
medication. The nationally weighted sum of ADHD medication cost was $6.62 billion 
(mean= $1,336, SD= $1,220). Amphetamine salts prescriptions were associated with 
the highest overall cost ($3.67 billion). Overall drug expenditure did not differ by 
gender or race. We found a higher proportion of males were diagnosed with ADHD 
than females (7.97% vs. 3.48%, P < 0.001). Diagnosis with ADHD was less frequent 
among white children as compared with African-American children (5.79% vs. 7.09%, 
P = 0.012). CONCLUSIONS: We found that 5.70% of 2010 U.S. pediatric visits had a 
mention of ADHD diagnosis. We estimated that in 2010 U.S. expenditure for ADHD 
medications was $6.62 billion. Diagnosis of ADHD was more frequent among males 
and African-American children and less frequent among females and whites.
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OBJECTIVES: The rate of remission with treatment in major depressive disorder (MDD) 
is low; thus, switching medication is common. This study describes MDD patients in 
the US who switched to selected antidepressants; determines the rates of switching, 
discontinuation, and adherence; and quantifies the healthcare costs following treat-
ment switch. METHODS: Adults with ≥ 2 MDD-related claims (ICD-9 codes: 296.2x, 
296.3x) from the Truven Health Analytics MarketScan (1Q2001-4Q2012) database, who 
switched from an antidepressant to bupropion, citalopram, desvenlafaxine, dulox-
etine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine, or 
vilazodone (index AD), were identified. The index date was the date of first treatment 
switch occurring on or after January 1, 2012. Continuous enrollment for ≥ 12 months 
prior to and ≥ 6 months following the index date was required. Patient and treatment 
characteristics during the 12-month baseline (i.e., pre-index) period are reported. 
Index antidepressant discontinuation (defined as a treatment gap of ≥ 45 consecutive 
days), adherence (defined as ≥ 80% of days covered with the index antidepressant), 
and switch rates (from the index antidepressant to another antidepressant) over 
the 6-month follow-up are reported. Healthcare costs incurred during the 6-month 
follow-up are also reported. RESULTS: 9,912 patients were included. On average, 
patients were 45.9 years old, and 72.7% were female. A mean of 1.9 antidepressants 
were prescribed during the baseline period. Patients had been on antidepressants for 
230.6 days, on average, at baseline. During the 6-month follow-up, 16.8% of patients 
switched treatment and 28.0% discontinued the index antidepressant. The proportion 
of adherent patients was 52.2%. Patients incurred an average total healthcare cost 
of $9,835 (2013 US$) during follow-up. CONCLUSIONS: Switching is prevalent, and 
a notable financial burden is observed among switchers in the US. Discontinuation 
rates are high, and adherence is suboptimal. Future research is warranted to deter-
mine which switching strategies are associated with optimal treatment and costs.
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OBJECTIVES: to determine the cost effectiveness of three treatment alternatives 
(medication, behavioral, and combined treatment of Atomoxetine and behavioral 
therapy) for attention deficit hyperactivity disorder in children from payer per-
spective with time horizon: 12 weeks METHODS: a prospective trial based eco-
nomic evaluation was conducted on children in psychiatric out patients clinic at 
Abasseya Mental Hospital (AMH), Cairo ,Egypt who are 6 to 12 years of age (boys or 
girls), and had a clinical diagnoses of ADHD as defined in the Diagnostic and sta-
tistical Manual fourth edition (DSM_IV). Patients were classified into three groups: 
(Depended on psychiatric recommendation and parents preferences) medication 
only group (group I), behavioral therapy group (group II), and combined medication 
and behavioral therapy group (group III). Each treatment had both a cost and an 
outcome associated with it. Cost effectiveness ratio comprising the average total 
cost per child per unit of outcome three months-Quality Adjusted Life Years “QALY” 
in each of the three groups. RESULTS: The combined therapy was associated with 
the highest cost effective ratio C/E Ratio of 7695.524 LE per QALY, medication therapy 
was 4381.927 LE per QALY, While C/E Ratio of behavioral therapy was 3337.339 LE 
per QALY. According to base-case analysis, combined therapy resulted in greatest 
health benefits but at the same time it was the most expensive treatment option. 
Behavioral therapy was the least effective and cheapest option. The sensitivity anal-
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yses: show that the utility values of all health states are crucial determinants of the 
cost-effectiveness results. CONCLUSIONS: combined therapy resulted in greatest 
health benefits but at the same time it was the most expensive treatment option. 
Behavioral therapy was the least effective and cheapest option.
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OBJECTIVES: The buprenorphine/naloxone (BUP/NAL) combination is used in the 
treatment of prescription opioid drug dependent (OPD) patients. Previous analy-
ses demonstrated that OPD patients receiving treatment vs. no treatment, were 
associated with a reduction in the number of admissions relating to emergency 
care and psychiatric services. The objective of this study was to compare resource 
utilisation and associated healthcare costs between the OPD patients treated with 
buprenorphine/naloxone combination and OPD patients without pharmacologi-
cal treatment from the German healthcare perspective. METHODS: Two patient 
groups were selected: 1) OPD patients treated with buprenorphine/naloxone and 
2) OPD patients with no pharmacological treatment. In the absence of accessible 
large longitudinal administrative claims database in Germany, the resource use 
was estimated based on the Truven Health MarketScan Medicaid (public healthcare 
claims) database from January 01, 2007 to December 31, 2013 as a representation 
of the German population. Resource use included pharmaceutical claims, inpa-
tient care, outpatient care, and urine tests, estimated over twelve months after 
the index date. Drug costs were obtained from the German-specific source (Gelbe 
List PharmIndex) and other unit costs and length of stays using Diagnostic Related 
Group (DRG) and Einheitlicher Bewertungsmasstab (EBM). Sensitivity analyses were 
performed. RESULTS: Costs for OPD patient receiving treatment were lower in all 
categories (inpatient care, outpatient care, and urine tests), except for BUP/NAL cost. 
Total costs over 12 months were 6,033€ and 6,244€ per OPD patient with and with-
out pharmacological treatment, respectively. CONCLUSIONS: Whilst a treatment 
of prescription opioid drug dependent patients with buprenorphine/naloxone is 
associated with a medication acquisition cost, it results in public healthcare savings 
when compared to patients receiving no medication treatment.
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OBJECTIVES: Obsessive compulsive disorder (OCD) is the fourth most common mental 
disorder in the UK with a prevalence of 1.5%. UK guidelines recommend either phar-
macological or cognitive behavioural therapy (CBT) for adults with moderate func-
tional impairment. This study estimates the cost effectiveness of pharmacological, 
psychological treatments and combinations of both in the treatment of adults with 
OCD. METHODS: A decision model evaluated the cost effectiveness of selective sero-
tonin re-uptake inhibitors ( SSRIs), venlafaxine (VEN), clomipramine (CLO), behaviour 
therapy (BT), cognitive behavioural therapy (CBT), cognitive therapy (CT), fluvoxam-
ine plus cognitive behavioural therapy (FLV+CBT) and clomipramine plus behaviour 
therapy (CLO + BT). Initial consequences of therapy (0-12 weeks) were modelled using 
a decision tree. Subsequent costs and outcomes were tracked in a Markov model. 
Treatment effects (response based on YBOCS scores) and tolerability (drop outs) were 
obtained from concurrent network meta-analyses. Discounted (3.5%) health service 
costs and benefits (QALYs) over a five year period were estimated, and probabilistic 
sensitivity analyses were conducted to assess robustness of findings. RESULTS: All 
psychological and combined psycho/pharmacotherapy were more costly and had 
better outcomes than pharmacotherapies alone. CT and BT had the highest prob-
abilities (both ≈0.35) of being most cost-effective at UK thresholds. The incremental 
cost per QALY of CBT and FLV+CBT versus SSRIs were £54,280 and £129,318 respec-
tively. CONCLUSIONS: The selection of the most cost-effective therapy for adults with 
OCD is not clear-cut. The high cost-effectiveness of CT and BT is sensitive to exclusion 
of RCTs at high risk of bias. Our results are not inconsistent with UK guidance and sug-
gest that CBT is slightly more efficacious than SSRIs, but is initially more expensive. 
If an SSRI is used, the choice of drug has important economic implications. Tailoring 
the format and intensity of CBT might make it more cost-effective.
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OBJECTIVES: Schizoaffective disorder (SCA) is a complex illness with interplay of 
psychosis and mood symptoms managed with non-optimal pharmacologic regi-
mens that include antipsychotics, mood stabilizers, and antidepressants.1 The 
15-month Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of 
Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective 
Disorder demonstrated the benefit in delayed relapses and reduced risk of relapse 
with paliperidone palmitate once-monthly injectable (PP1M).2 This analysis esti-
mated medical costs differences among patients treated with PP1M monotherapy 
or PP1M adjunctive therapy to antidepressants or mood stabilizers versus pla-
cebo. METHODS: Rates of relapses and serious and non-serious treatment-emer-
gent adverse events (TEAEs) were derived from the trial data. Incremental annual 
medical costs for clinical events from a U.S. payer perspective were obtained from 
literatures and inflation adjusted to 2014 costs. Mean differences in total annual 
medical costs for patients treated with PP1M monotherapy and adjunctive therapy 
versus placebo were then estimated. One-way and Monte Carlo sensitivity analyses 
were additionally carried out. RESULTS: A lower rate of relapses (adjunctive therapy: 
-15.42%; monotherapy: -21.34%) and serious TEAEs (both PP1M cohorts: -3.92%) were 
associated with use of PP1M versus placebo. The average annual medical cost-offset 
per patient was -$8320.92 for monotherapy and -$6030.65 for adjunctive therapy 
driven by reduction in relapse rates and serious TEAEs. One-way sensitivity analysis 
showed that variations in relapse rates had the greatest impact on the estimated 
medical cost difference (monotherapy range: -$11,036.64, -$4,684.93; adjunctive 
therapy range: -$9,650.33, -$1,372.78). CONCLUSIONS: Use of PP1M was associated 
with significantly lower relapse rates and consequently a substantial reduction in 
medical costs. Patients treated with PP1M monotherapy resulted in even a greater 
medical cost saving. Further evaluation to assess the impact of monotherapy option 
in real-world setting is warranted.
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OBJECTIVES: Reductions in prices following the expiry of patents on second-
generation antipsychotics means that they could be made available to patients 
with Schizophrenia in low-income countries. In this study we examine the cost-
effectiveness of of 5 antipsychotics—chlorpromazine, haloperidol, risperidone, 
olanzapine and quetiapine—for the treatment of Schizophrenia in Uganda to 
inform national-level policy and clinical decision making. METHODS: We devel-
oped a decision-analytic 3-state (outpatient, inpatient, and dead) Markov model 
to represent the clinical course of Schizophrenia and the experience of the aver-
age patient with the Uganda healthcare system. The model was run for a base 
population of 18-year-old patients attending Butabika National Referral Mental 
Hospital, in 3-monthly cycles over a lifetime horizon. Parameters were derived 
from a primary chart abstraction study, a local community pharmacy survey, 
published literature and expert opinion where necessary. We computed mean 
DALYs and costs (in $US) for each antipsychotic, incremental cost and DALYs 
averted as well as Incremental Cost Effectiveness Ratios (ICER). RESULTS: In the 
base-case analysis, mean DALYs were highest with chlorpromazine (30.17), fol-
lowed by haloperidol (29.48), while olanzapine (28.90) and risperidone had the 
lowest DALYs (28.99). Expected costs were highest with quetiapine ($6,777), and 
lowest with haloperidol ($6,404). Compared to chlorpromazine, haloperidol was 
a dominant strategy (i.e., it was less costly and more effective). ICERs comparing 
risperidone to haloperidol and olanzapine to risperidone were $372 and $1400 
per DALY averted. CONCLUSIONS: Policy makers and clinicians should consider 
haloperidol as the first line agent for Schizophrenia in Uganda. Further, at com-
monly accepted thresholds (between 1 and 3 times the Gross Domestic Product 
of Uganda), risperidone is highly cost-effective and olanzapine is cost-effective, 
therefore policymakers should consider adding these agents to essential medi-
cines lists for treatment of Schizophrenia.
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OBJECTIVES: The primary objective was to estimate incremental cost-effectiveness 
of vortioxetine, a serotonin modulator and simulator (SMS) versus desvenlafaxine, 
a serotonin-norepinephrine reuptake inhibitor (SNRI), as potential first line medi-
cations for treatment of mild or moderate major depression. The clinical benefit 
of a SMS may be in faster onset and shorter time to remission. Evidence suggests 
vortioxetine causes fewer adverse drug events (ADEs) than desvenlafaxine, which 
has implications for discontinuation of therapy. METHODS: A decision tree was 
constructed to model the cost effectiveness of these two agents from the societal 
perspective. Parameters were obtained from published clinical trial data, a meta-
analysis using indirect treatment comparison, observational studies, preference 
elicitation studies, and cost estimates from Average Wholesale Prices for medica-
tions and claims analyses for cost of medical care. The model assumed that patients 
achieved remission. The time horizon was 48 weeks and included opportunities 
to switch medication therapy at 8 weeks and relapse at 24 weeks. Incremental 
cost-effectiveness ratios (ICERs) were calculated using the number of discontinu-
ations averted, relapses averted, and quality adjusted life years (QALYs) gained as 
outcomes. One-way sensitivity analyses were conducted. RESULTS: The ICER was 
$77,800 per QALY gained, $59,500 per relapse averted, and $58,500 per averted dis-
continuation due to ADEs. The parameter that was least robust was a utility value 
of maintenance therapy for vortioxetine or desvenlafaxine applied to weeks 8-48 
(0.80, range: 0.78-0.82; 0.76, range 0.74-0.78, respectively). Time to remission was 
varied from 6-10 weeks. A shorter time to remission for vortioxetine provided mod-
est improvements in the ICER while a longer time to remission increased cost over 
the point estimate of $77,800 per QALY gained ($69,000-$88,900 per QALY gained, 
respectively). CONCLUSIONS: Model results suggest that there is value in invest-
ing in vortioxetine over desvenlafaxine. A potentially faster time to remission for 
vortioxetine would result in increased value.
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